New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 13, 2014
14:41 EDTACT, MNK, QCORFDA approval of generic Exalgo negative for Mallinckrodt, says BMO Capital
BMO Capital thinks the FDA's approval of Actavisí (ACT) generic version of Exalgo was expected, but the firm still views it as a near-term negative for Mallinckrodt (MNK). BMO expects Mallinckrodt's raised guidance and pending accretive Questcor (QCOR) deal to support the stock longer-term and maintains an Outperform rating on Mallinckrodt.
News For ACT;QCOR;MNK From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
There are no results for ACT;QCOR;MNK

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the theflyonthewall.com disclaimer & terms of use